article thumbnail

Beyond Glycemic Control: Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist to Reduce the Burden of Peripheral Artery Disease

American College of Cardiology

Over the past decade, lipid-lowering therapies have established the low-density lipoprotein-cholesterol dogma of the lower, the earlier, the longer, the better as the cornerstone of pharmacological prevention for atherosclerotic cardiovascular disease (ASCVD).

article thumbnail

A Practical Guide to Understanding and Treating Peripheral Artery Disease

Journal of Cardiovascular Pharmacology

Peripheral arterial disease (PAD) is the third leading cause of atherosclerotic morbidity after coronary heart disease and stroke yet is widely underdiagnosed and undertreated. Treatment of risk factors such as diabetes and cigarette smoking can benefit patients with PAD.

article thumbnail

Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis

Circulation

Using mediation Mendelian randomization, we explored proteomic mediators of the effects of genetically proxied IL-6 signaling on coronary artery disease, large artery atherosclerotic stroke, and peripheral artery disease.

article thumbnail

CLINICAL PERFORMANCE AND PERSISTENCE ON DUAL PATHWAY INHIBITION WITH RIVAROXABAN AND ASPIRIN IN REAL-WORLD SETTING.

Journal of Cardiovascular Pharmacology

Our observational study aimed to describe the clinical performance, adherence and persistence of DPI therapy among a real-world setting of patients with an established diagnosis of coronary artery (CAD) and/or peripheral artery disease (PAD). The adherence to pharmacological treatment was 99%.Additionally,

article thumbnail

New Guidelines on Peripheral Artery Disease Issued by American Heart Association, American College of Cardiology and Leading Medical Societies

DAIC

A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).

article thumbnail

Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain

Frontiers in Cardiovascular Medicine

Patients with a new or recurrent episode of ASCVD (angina, acute myocardial infarction, transient ischemic attack, stroke, or peripheral arterial disease) between 1-Jan-2017 and 31-Dec-2018 were included. The costs derived from pharmacological treatments were obtained from the NHS pricing nomenclator database ( [link] ).

article thumbnail

Impact of In-Hospital Bleeding on Post-Discharge Therapies and Prognosis in Acute Coronary Syndromes.

Journal of Cardiovascular Pharmacology

Age, female sex, hypertension, and peripheral artery disease were found to be independent predictors of IHB, while DES implantation, radial access and left ventricular ejection fraction were identified as protective factors. 95% CI 0.92.11; p = 0.149).